56.92

0.22% 0.0994

Crinetics Pharmaceuticals Inc (CRNX)

Overview News Price History Option Chain Financials Why CRNX Down? Discussions Forecast

Crinetics Pharmaceuticals Inc stock is traded at $56.92, with a volume of 114.92K. It is up +0.22% in the last 24 hours and up +7.16% over the past month. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Previous Close:

$56.82

Open:

$56.49

24h Volume:

114.92K

Relative Volume:

0.18

Market Cap:

$5.11B

Revenue:

$4.72M

Net Income/Loss:

$-214.53M

P/E Ratio:

-16.69

EPS:

-3.41

Net Cash Flow:

$-171.00M

1W Performance:

+1.21%

1M Performance:

+7.16%

6M Performance:

+20.64%

1Y Performance:

+85.48%

1-Day Range:

$55.28

$57.16

1-Week Range:

$54.32

$58.00

52-Week Range:

$25.75

$60.04

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name

Crinetics Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-450-6464

Address

10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA

Employee

210

Twitter

@Crinetics

Next Earnings Date

2024-11-12

Latest SEC Filings

CRNX's Discussions on Twitter

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-24	Initiated	Citigroup	Buy
Jan-16-24	Initiated	Morgan Stanley	Overweight
Dec-21-23	Initiated	Jefferies	Hold
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-31-23	Initiated	Oppenheimer	Outperform
Apr-24-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Robert W. Baird	Outperform
Nov-30-21	Initiated	JMP Securities	Mkt Outperform
Nov-23-21	Initiated	Evercore ISI	Outperform
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-23-19	Initiated	ROTH Capital	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Aug-13-18	Initiated	JP Morgan	Neutral
Aug-13-18	Initiated	Leerink Partners	Outperform
Aug-13-18	Initiated	Piper Jaffray	Overweight

View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

11:26 AM

(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily

11:26 AM

06:31 AM

Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday - MarketBeat

06:31 AM

04:09 AM

abrdn plc Cuts Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

04:09 AM

02:12 AM

Vanguard Group Inc's Strategic Acquisition in Crinetics Pharmace - GuruFocus.com

02:12 AM

Nov 04, 2024

Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Nov 04, 2024

Oct 30, 2024

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Yahoo Finance

Oct 30, 2024

Oct 24, 2024

Moody Aldrich Partners LLC Sells 11,053 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Oct 24, 2024

Oct 22, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year HighHere's What Happened - MarketBeat

Oct 22, 2024

Oct 20, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 20, 2024

Oct 17, 2024

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Crinetics Pharmaceuticals outlines executive transition By Investing.com - Investing.com Australia

Oct 16, 2024

Crinetics Pharmaceuticals’ $500 Million Common Stock Offering - Global Legal Chronicle

Oct 16, 2024

Crinetics Pharmaceuticals outlines executive transition - Investing.com India

Oct 16, 2024

Crinetics Pharmaceuticals Inc’s results are impressive - US Post News

Oct 16, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month HighWhat's Next? - MarketBeat

Oct 16, 2024